Who are Tamoxifen, Letrozole, Anastrozole or Exemestane's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tamoxifen-letrozole-anastrozole-or-exemestane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Tamoxifen, Letrozole, Anastrozole or Exemestane — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamoxifen, Letrozole, Anastrozole or Exemestane (Tamoxifen, Letrozole, Anastrozole or Exemestane) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane). Area: Oncology.

marketed Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane) Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tamoxifen, Letrozole, Anastrozole or Exemestane (Tamoxifen, Letrozole, Anastrozole or Exemestane) — Institut Claudius Regaud. These drugs block estrogen signaling in breast cancer cells, either by directly antagonizing the estrogen receptor (tamoxifen) or by inhibiting aromatase to reduce estrogen production (letrozole, anastrozole, exemestane).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamoxifen, Letrozole, Anastrozole or Exemestane TARGET	Tamoxifen, Letrozole, Anastrozole or Exemestane	Institut Claudius Regaud	marketed	Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane)	Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane) class)

Institut Claudius Regaud · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tamoxifen, Letrozole, Anastrozole or Exemestane — Competitive Intelligence Brief. https://druglandscape.com/ci/tamoxifen-letrozole-anastrozole-or-exemestane. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab